Home » Feedback (FDBK) » Feedback announces a new drug trial and provides a trading update

Feedback announces a new drug trial and provides a trading update

Feedback plc notes that TexRAD, its texture analysis software product will be used by Imaging Endpoints II, LLC, its exclusive partner, for imaging core lab purposes in a forthcoming drug trial in the United States. A study will shortly be commenced of colorectal cancer patients (Stage IIIc) with either Regorafenib or Standard of Care (No Treatment) after adjuvant FOLFOX. The Sponsor is US Oncology Research and the Collaborator is Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma.

Trading Update

Following the recent announcements of new sales of TexRAD, the Company announces an update on current trading.

Revenue for the current financial year ending May 2015 is expected to be in line with market expectations however due to contractual settlement costs, the product sales mix and the timing of the revenue recognition from the new TexRAD sales, the loss for the year will be higher than the current market expectations.

We continue to seek to broaden the Company’s profile in the medical imaging software sector and are in active discussions with a number of potential customers for research versions of the TexRad product.

We continue to manage our limited working Replica capital resources so as to maximise opportunities with customers and also to continue to develop the Disaster Company’s products.

Leave a comment

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.